成人急性淋巴细胞白血病的强化治疗:随机GRAALL-2005临床试验报告
GRAALL-2005随机试验纳入787例新诊断费城染色体阴性急性淋巴细胞白血病成人患者,比较标准剂量环磷酰胺与超分割环磷酰胺(hyper-C)强化方案。中位随访5.2年,5年无事件生存(EFS)率52.2%,总生存(OS)率58.5%,hyper-C未提高完全缓解率或延长EFS、OS。≥55岁患者对强化方案耐受性差,但该组从hyper-C获益显著。
要点
- hyper-C方案未提高完全缓解率,也未延长EFS或OS。
- 5年EFS率:<55岁患者55.7% vs ≥55岁患者25.8%(HR 2.16;P<.001)。
- ≥55岁患者从hyper-C获益显著,<55岁患者未获益。
核心结论
- 在儿童样方案治疗成人急性淋巴细胞白血病时,加入hyper-C序列未带来显著获益。
- ≥55岁患者对儿童来源的强化治疗总体耐受性差。
研究设计与样本
- 随机对照临床试验GRAALL-2005,共787例可评估患者(B系525例,T系262例;中位年龄36.1岁)。
- 患者随机分配至首次诱导和晚期强化期间接受标准剂量环磷酰胺或hyper-C。
- 化疗依从性通过每个治疗阶段实际接受的中位剂量评估。
主要发现
- 总体完全缓解率为91.9%。
- 中位随访5.2年,5年EFS率为52.2%(95%CI 48.5%~55.7%),5年OS率为58.5%(95%CI 54.8%~61.9%)。
- 随机分配至hyper-C组未提高完全缓解率,也未延长EFS或OS。
- 5年EFS率:<55岁患者55.7%(95%CI 51.8%~59.4%)vs ≥55岁患者25.8%(95%CI 19.9%~35.6%)(HR 2.16;P<.001)。
- ≥55岁患者对全部计划化疗的依从性较低,但该组从hyper-C获益显著;<55岁患者未获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To evaluate randomly the role of hyperfractionated cyclophosphamide (hyper-C) dose intensification in adults with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia treated with a pediatric-inspired protocol and to determine the upper age limit for treatment tolerability in this context. Patients and Methods A total of 787 evaluable patients (B/T lineage, 525 and 262, respectively; median age, 36.1 years) were randomly assigned to receive a standard dose of cyclophosphamide or hyper-C during first induction and late intensification. Compliance with chemotherapy was assessed by median doses actually received during each treatment phase by patients potentially exposed to the full planned doses. Results Overall complete remission (CR) rate was 91.9%. With a median follow-up of 5.2 years, the 5-year rate of event-free survival (EFS) and overall survival (OS) was 52.2% (95% CI, 48.5% to 55.7%) and 58.5% (95% CI, 54.8% to 61.9%), respectively. Randomization to the hyper-C arm did not increase the CR rate or prolong EFS or OS. As a result of worse treatment tolerance, advanced age continuously affected CR rate, EFS, and OS, with 55 years as the best age cutoff. At 5 years, EFS was 55.7% (95% CI, 51.8% to 59.4%) for patients younger than 55 years of age versus 25.8% (95% CI, 19.9% to 35.6%) in older patients (hazard ratio, 2.16; P < .001). Patients ≥ 55 years of age, in whom a lower compliance to the whole planned chemotherapy was observed, benefited significantly from hyper-C, whereas younger patients did not. Conclusion No significant benefit was associated with the introduction of a hyper-C sequence into a frontline pediatric-like adult acute lymphoblastic leukemia therapy. Overall, tolerability of an intensive pediatric-derived treatment was poor in patients ≥ 55 years of age.
引用
- Huguet F, Chevret S, Leguay T, et al. Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial. J Clin Oncol. 2018. PMID: 29863974. doi:10.1200/JCO.2017.76.8192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。